Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IX
Paul A. Fields, Dariusz W Kowalczyk, Valder R. Arruda et al. · Molecular Therapy · 2000
Defining immune responses against the secreted transgene product in a gene therapy setting is critical for treatment of genetic diseases such as hemophilia B (coagulation factor IX deficiency). We have previously shown that intramuscular administration of an adeno-associated viral (AAV) vector results in stable expression of therapeutic levels of factor IX (F.IX) and may be associated with humoral immune responses against F.IX. This study demonstrates that intramuscular injection of an AAV vector expressing F.IX fails to activate F.IX-specific cytotoxic T lymphocytes (CTLs) in hemostatically normal or in hemophilia B mice, so that there is an absence of cellular immune responses against F.IX. However, transgene-derived F.IX can cause B cell responses characterized by production of T helper cell-dependent antibodies (predominantly IgG1, but also IgG2 subclasses) resulting from activation of CD4+ T helper cells primarily of the Th2 subset. In contrast, administration of an adenoviral vector efficiently activated F.IX-specific CTLs and T helper cells of both Th1 and Th2 subsets, leading to inflammation and destruction of transduced muscle tissue and activation of B cells as well. Therefore, vector sequences fundamentally influence T cell responses against transgene-encoded F.IX. In conclusion, activation of the immune system in AAV-mediated gene transfer is restricted to pathways mediated by F.IX antigen presentation through MHC class II determinants resulting in T and B cell responses that are more comparable to responses in the setting of protein infusion rather than of viral infection/gene transfer.
Cited by 129 works. doi:10.1006/mthe.2000.0032 Open-access PDF
Authors
- Dariusz W Kowalczyk
- Valder R. Arruda
- Elina Armstrong
- Mark L. McCleland
- J. Nathan Hagstrom
- John Pasi
- Hildegund C.J. Ertl
- Roland W. Herzog
- Katherine A. High
References
- RAG-1-deficient mice have no mature B and T lymphocytes
- Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector
- Recombinant adeno-associated virus for muscle directed gene therapy
- Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.
- Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein
- IgG2a restriction of murine antibodies elicited by viral infections.
- Immune responses to transgene–encoded proteins limit the stability of gene expression after injection of replication–defective adenovirus vectors
- Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.
- Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
- INFLUENCE OF DOSE AND ROUTE OF ANTIGEN INJECTION ON THE IMMUNOLOGICAL INDUCTION OF T CELLS